TY - JOUR
T1 - Review of management priorities for invasive infections in people who inject drugs
T2 - highlighting the need for patient-centred multidisciplinary care
AU - Attwood, Lucy O.
AU - McKechnie, Megan
AU - Vujovic, Olga
AU - Higgs, Peter
AU - Lloyd-Jones, Martyn
AU - Doyle, Joseph S.
AU - Stewardson, Andrew J.
N1 - Funding Information:
The authors acknowledge the work of Thuy Bui and Kelly Cairns for their assistance reviewing the pharmacology in this article. The Burnet Institute acknowledges support from the Victorian Government Operational Infrastructure Fund. Lucy Attwood receives postgraduate support from the Australian National Health and Medical Research Council (NHMRC). Joseph Doyle and Andrew Stewardson receive Fellowship support from the NHMRC.
Funding Information:
Peter Higgs has received investigator‐driven research funding from Gilead Sciences and AbbVie for work on hepatitis C unrelated to this manuscript. Martyn Lloyd‐Jones has received honoraria for giving lectures and educational sessions organised by Indivior. Joseph Doyle’s institution has received investigator‐initiated research funding from Gilead Sciences and AbbVie and honoraria from Gilead Sciences and AbbVie.
Publisher Copyright:
© 2022 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.
PY - 2022/7
Y1 - 2022/7
N2 - There has been a global increase in the burden of invasive infections in people who inject drugs (PWID). It is essential that patient-centred multidisciplinary care is provided in the management of these infections to engage PWID in care and deliver evidence-based management and preventive strategies. The multidisciplinary team should include infectious diseases, addictions medicine (inclusive of alcohol and other drug services), surgery, psychiatry, pain specialists, pharmacy, nursing staff, social work and peer support workers (where available) to help address the comorbid conditions that may have contributed to the patient’s presentation. PWID have a range of antimicrobial delivery options that can be tailored in a patient-centred manner and thus are not limited to prolonged hospital admissions to receive intravenous antimicrobials for invasive infections. These options include discharge with outpatient parenteral antimicrobial therapy, long-acting lipoglycopeptides (dalbavancin and oritavancin) and early oral antimicrobials. Open and respectful discussion with PWID including around harm reduction strategies may decrease the risk of repeat presentations with injecting-related harms.
AB - There has been a global increase in the burden of invasive infections in people who inject drugs (PWID). It is essential that patient-centred multidisciplinary care is provided in the management of these infections to engage PWID in care and deliver evidence-based management and preventive strategies. The multidisciplinary team should include infectious diseases, addictions medicine (inclusive of alcohol and other drug services), surgery, psychiatry, pain specialists, pharmacy, nursing staff, social work and peer support workers (where available) to help address the comorbid conditions that may have contributed to the patient’s presentation. PWID have a range of antimicrobial delivery options that can be tailored in a patient-centred manner and thus are not limited to prolonged hospital admissions to receive intravenous antimicrobials for invasive infections. These options include discharge with outpatient parenteral antimicrobial therapy, long-acting lipoglycopeptides (dalbavancin and oritavancin) and early oral antimicrobials. Open and respectful discussion with PWID including around harm reduction strategies may decrease the risk of repeat presentations with injecting-related harms.
KW - Addiction
KW - Anti-infective agents
KW - Bacterial infections
KW - Cardiovascular infections
KW - Harm reduction
KW - Substance abuse, intravenous
KW - Substance-related disorders
UR - http://www.scopus.com/inward/record.url?scp=85132778797&partnerID=8YFLogxK
U2 - 10.5694/mja2.51623
DO - 10.5694/mja2.51623
M3 - Review Article
C2 - 35754144
AN - SCOPUS:85132778797
SN - 0025-729X
VL - 217
SP - 102
EP - 109
JO - The Medical Journal of Australia
JF - The Medical Journal of Australia
IS - 2
ER -